UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026
UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 utmd_ex99z1.htm EXHIBIT 99.1 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026 Contact: Brian Koopman (801) 566-1200 July 23, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar qua
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
UTMD’s results show a concentrated revenue decline tied to the loss of two previously largest customers, plus higher U.S. litigation costs that reduce operating income. Cash remains strong with no debt, which may support liquidity despite earnings pressure.
Market read
Traders can reassess near-term earnings trajectory based on the disclosed revenue shortfall drivers and litigation cost increases, while monitoring whether new biopharma OEM customers can offset lost volume.
What to watch
The filing notes constant-currency foreign sales are down materially, but also that excluding the former China distributor, OUS sales were higher, implying some geographic/customer stabilization not captured by headline totals.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 detailing UTMD’s 2Q and 1H 2026 financial performance and drivers versus 2025.
Ticker impact
UTMD reports 2Q and 1H 2026 revenue declines, citing zero sales to PendoTECH and higher U.S. litigation costs impacting operating income.
Likely negative-to-neutral near term as investors focus on customer loss (PendoTECH) and litigation cost drag, partially offset by strong cash and no debt.
The filing provides specific quarterly and half-year revenue deltas, margin changes, and litigation cost increases, which are direct drivers of earnings power. However, it does not provide full-year guidance or a new resolution/settlement, limiting upside catalysts.
Market effects
Biopharma OEM and medical device distribution demand appears uneven, with customer concentration risk highlighted by the PendoTECH sales drop.
Limited FX impact is noted, suggesting reported declines are more operational than currency-driven.
International sales are down, but the company attributes most of the decline to specific customer/distributor losses rather than broad global demand collapse.
Counterpoint
The company reports strong balance sheet metrics (no debt, cash and investments up slightly), which may reduce downside risk if litigation costs are temporary.
Key entities
- companyUtah Medical Products, Inc.
Nasdaq-listed medical device company reporting 2Q and 1H 2026 results, including revenue declines and higher litigation costs.
- customerPendoTECH
Previously largest OEM customer; UTMD reports zero sales to PendoTECH in 2Q and 1H 2026.
